Das könnte Sie auch interessieren:

Neuer Opel Zafira Life: So clever kann groß sein

Rüsselsheim (ots) - - In neuer Dimension: Die nächste Generation des Großraum-Pkw fährt vor - In ...

Handball-WM 2019: Deutschland gegen Frankreich am Dienstag live im ZDF

Mainz (ots) - Nach den beiden überzeugenden Auftritten gegen Korea und Brasilien sowie dem heutigen Spiel gegen ...

Kraftvolle Kooperation: Fitness-Magazin SHAPE launcht "Sophia Thiel Magazin" / Ab 9. Januar 2019 im Handel

München (ots) - Sie war die erste Influencerin auf der Titelseite von SHAPE. Jetzt wachsen die starken Marken ...

22.10.2010 – 10:02

Epigenomics AG

EANS-News: Epigenomics AG to Update on Clinical Studies with Septin9 Blood Test for Colorectal Cancer at Two Conferences in Europe and the US

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.

Company Information/Molecular diagnostics

BERLIN and SEATTLE - October 22, 2010 (euro adhoc) - Epigenomics AG, the cancer diagnostics company, today announced that it will present data from two clinical studies with its proprietary biomarker for the blood-based detection of colorectal cancer at two conferences in Europe and the US during the next week.

The two poster presentations will include data form the recently successfully completed prospective PRESEPT Study as well as a follow-up study performed to independently validate the diagnostic assay that had been used in the PRESEPT Study.

On Tuesday, October 26, 2010, Dr. Juergen Beck, M.D., Senior Vice President Medical Affairs at Epigenomics, will present clinical data at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain.

Joseph Romagnuolo M.D., Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at the Medical University of South Carolina will present study data at the American Association for Cancer Research (AACR) Special Conference "Colorectal Cancer: Biology to Therapy" in Philadelphia, PA, USA on Friday, October 29, 2010.

Prof. Romagnuolo participated as a Clinical Investigator in the PRESEPT Study.

Conference Presentation Details

18th United European Gastroenterology Week (UEGW) October 23-28, 2010 Centre Convencions Internacional Barcelona CCIB, Barcelona, Spain Poster Presentation: Poster P0990 October 26, 2010, 9 am - 5 pm

AACR Special Conference "Colorectal Cancer: Biology to Therapy" October 27- 30, 2010 Loews Philadelphia Hotel, Philadelphia, Pennsylvania, USA Poster Presentation: Poster Session B, Board B29 October 29, 2010, 5 pm - 7 pm

- Ends-

Contact Epigenomics AG:

Dr. Achim Plum 

Sen. VP Corporate Development Epigenomics AG Tel +49 (0) 30 24345 368 pr@epigenomics.com www.epigenomics.com

Notes to Editors

About Epigenomics

Epigenomics AG is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics´ tests on the market and in development for colorectal, lung, and prostate cancer aim at aiding in an earlier and more accurate diagnosis of these diseases thereby potentially increasing the patient´s chances of survival.

For development and global commercialization of IVD test products, Epigenomics pursues a dual business strategy in which direct commercialization of proprietary diagnostic test products is combined with non-exclusive licensing to diagnostic industry players with broad customer access. Strategic diagnostics industry partners include Abbott Molecular, Sysmex Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories, Inc. for diagnostics test products and services, and QIAGEN N.V. for sample preparation solutions and research products.

The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more information, please visit Epigenomics´ website at www.epigenomics.com.

Epigenomics´ legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward- looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States of America. The analytical and clinical performance characteristics of any product based on this technology which may be sold at some future time in the USA have not been established.

end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368

Branche: Biotechnology
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Original-Content von: Epigenomics AG, übermittelt durch news aktuell

Alle Meldungen
Abonnieren Sie alle Meldungen von Epigenomics AG
  • Druckversion
  • PDF-Version

Themen in dieser Meldung